Deferiprone: differenze tra le versioni

Versione delle 18:47, 9 lug 2010

Versione delle 18:51, 9 lug 2010

Riga 47:

* ''Oral deferiprone for iron chelation in people with thalassaemia'' <ref name="pmid17636775">{{cite journal | author = Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ | title = Oral deferiprone for iron chelation in people with thalassaemia | journal = Cochrane Database of Systematic Reviews (Online) | volume = | issue = 3 | pages = CD004839 | year = 2007 | pmid = 17636775 | doi = 10.1002/14651858.CD004839.pub2 | url = http://dx.doi.org/10.1002/14651858.CD004839.pub2 | issn = | accessdate = 2010-07-09}}</ref>

* ''Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia'' <ref name="pmid16235363">{{cite journal | author = Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S | title = Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia | journal = Cochrane Database of Systematic Reviews (Online) | volume = | issue = 4 | pages = CD004450 | year = 2005 | pmid = 16235363 | doi = 10.1002/14651858.CD004450.pub2 | url = http://dx.doi.org/10.1002/14651858.CD004450.pub2 | issn = | accessdate = 2010-07-09}}</ref>

* ''Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)'' <ref name="pmid10206077">{{cite journal | author = Addis A, Loebstein R, Koren G, Einarson TR | title = Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). | journal =Eur EuropeanJ JournalClin ofPharmacol Clinical| Pharmacologyyear= 1999 | volume = 55 | issue = 1 | pages = 1–6 | year = 1999 | month = March1-6 | pmid = 10206077 | doi = | url = | issn = | accessdate = 2010-07-09}}</ref>

| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10206077 }} </ref>

== Controindicazioni ==